Lowenthal Richard E 4

4 · ARS Pharmaceuticals, Inc. · Filed Aug 22, 2025

Form 4

Period: 2025-08-21

DirectorPRESIDENT AND CEO10% Owner

Transactions

Sale
Common Stock
2025-08-21$14.49/sh−50,000$724,345→ 1,196,494 total(indirect: By Trust)

Holdings

Footnotes (6)

[F1]The shares were sold pursuant to a Rule 10b5-1 trading plan entered into on May 15, 2025.
[F2]The weighted average sale price for the transaction reported was $14.4869 and the range of prices were between $14.31 and $14.61. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
[F3]The Reporting Person is trustee of the trust.
[F4]The Reporting Person's spouse is trustee of the trust. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
[F5]The number of shares reported is comprised of (i) 1,098,499 shares that were previously reported as indirectly held by the Family Trust, (ii) 3,433,512 shares that were previously reported as indirectly held by the Reporting Person's spouse, and (iii) 4,327,189 shares that were previously reported as directly held by the Reporting Person.
[F6]The shares are held in trust for the benefit of the Reporting Person and his spouse. The Reporting Person and his spouse are trustees of the trust.

Documents

1 file